首页 > 最新文献

Medicina-buenos Aires最新文献

英文 中文
[Sudden death recovered: Brugada syndrome, a wolf in sheep's clothing]. [猝死康复:Brugada综合征,披着羊皮的狼]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Carlos Paz, Ángeles Pérez, Sergio Mauras, Gabriela Davis, Francisco Femenia, Josep Brugada

Brugada syndrome is a hereditary channelopathy associated with a high risk of sudden cardiac death in young individuals. We present the case of a 25-yearold man with a syncopal episode, without prodromes or defenses, during physical activity and a bilateral mandible fracture, who had a recovered sudden death during surgical repair.

Brugada综合征是一种遗传性通道病,与年轻人心源性猝死的高风险相关。我们提出一个病例25岁的男子晕厥发作,没有前体症状或防御,在体力活动和双侧下颌骨骨折,在手术修复期间恢复猝死。
{"title":"[Sudden death recovered: Brugada syndrome, a wolf in sheep's clothing].","authors":"Carlos Paz, Ángeles Pérez, Sergio Mauras, Gabriela Davis, Francisco Femenia, Josep Brugada","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Brugada syndrome is a hereditary channelopathy associated with a high risk of sudden cardiac death in young individuals. We present the case of a 25-yearold man with a syncopal episode, without prodromes or defenses, during physical activity and a bilateral mandible fracture, who had a recovered sudden death during surgical repair.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"247-250"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Functional status by Katz Index and outcomes in hospitalization in Medical Clinic]. [用Katz指数评价住院患者的功能状况及转归]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Ricardo E Barcia, Julieta Larralde

Introduction: Assessing functional status upon hospital admission helps identify patients at higher risk. The Katz Index is a validated tool that measures the ability to perform basic activities of daily living (ADLs). This study aimed to determine whether functional dependence, assessed via the Katz Index, is associated with higher in-hospital mortality in patients admitted to the Internal Medicine Service of the Hospital Naval Pedro Mallo.

Materials and methods: A prospective, observational cohort study was conducted between January 1 and December 31, 2024. Patients aged ≥15 years were included. They were classified as non-dependent (Katz A) or dependent (Katz B-G) upon admission. Demographic variables, diagnoses, length of stay, and outcomes were analyzed. Descriptive and comparative statistics were used, along with multivariate logistic regression.

Results: A total of 1293 patients were evaluated. Functional dependence (Katz B-G) was observed in 38% of patients. Overall mortality was 13%, significantly higher among dependent patients (25%) compared to non-dependent patients (6%) (RR 5.2; 95% CI: 3.6-7.4, p < 0.001). In the multivariate model, functional status, age, length of stay, pneumonia, and cancer were independent predictors of mortality.

Discussion: Functional dependence at admission, as measured by the Katz Index, is a common condition and a significant predictor of in-hospital mortality. Its assessment should be implemented as a routine evaluation tool upon admission.

在入院时评估功能状态有助于识别高危患者。卡茨指数是一种经过验证的工具,用于衡量进行基本日常生活活动(ADLs)的能力。本研究旨在确定通过卡茨指数评估的功能依赖是否与佩德罗·马洛海军医院内科服务部收治的患者较高的住院死亡率相关。材料和方法:一项前瞻性、观察性队列研究于2024年1月1日至12月31日进行。纳入年龄≥15岁的患者。他们在入院时被分类为非依赖性(Katz A)或依赖性(Katz B-G)。分析了人口统计学变量、诊断、住院时间和结果。使用描述性统计和比较统计,以及多变量逻辑回归。结果:共评估1293例患者。38%的患者出现功能依赖(Katz B-G)。总死亡率为13%,依赖患者(25%)明显高于非依赖患者(6%)(RR 5.2; 95% CI: 3.6-7.4, p < 0.001)。在多变量模型中,功能状态、年龄、住院时间、肺炎和癌症是死亡率的独立预测因子。讨论:入院时的功能依赖,通过Katz指数来衡量,是一种常见的情况,也是住院死亡率的重要预测因素。其评估应作为入院时的常规评估工具实施。
{"title":"[Functional status by Katz Index and outcomes in hospitalization in Medical Clinic].","authors":"Ricardo E Barcia, Julieta Larralde","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Assessing functional status upon hospital admission helps identify patients at higher risk. The Katz Index is a validated tool that measures the ability to perform basic activities of daily living (ADLs). This study aimed to determine whether functional dependence, assessed via the Katz Index, is associated with higher in-hospital mortality in patients admitted to the Internal Medicine Service of the Hospital Naval Pedro Mallo.</p><p><strong>Materials and methods: </strong>A prospective, observational cohort study was conducted between January 1 and December 31, 2024. Patients aged ≥15 years were included. They were classified as non-dependent (Katz A) or dependent (Katz B-G) upon admission. Demographic variables, diagnoses, length of stay, and outcomes were analyzed. Descriptive and comparative statistics were used, along with multivariate logistic regression.</p><p><strong>Results: </strong>A total of 1293 patients were evaluated. Functional dependence (Katz B-G) was observed in 38% of patients. Overall mortality was 13%, significantly higher among dependent patients (25%) compared to non-dependent patients (6%) (RR 5.2; 95% CI: 3.6-7.4, p < 0.001). In the multivariate model, functional status, age, length of stay, pneumonia, and cancer were independent predictors of mortality.</p><p><strong>Discussion: </strong>Functional dependence at admission, as measured by the Katz Index, is a common condition and a significant predictor of in-hospital mortality. Its assessment should be implemented as a routine evaluation tool upon admission.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"26-35"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Sarcomatoid variant of adrenocortical carcinoma]. [肾上腺皮质癌的肉瘤样变异]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Silvina Fili, Daniel Moncet, Jorge Zoppi

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis and limited response to current therapies. The sarcomatoid subtype represents the rarest and most aggressive form of ACC, with very few cases reported in the literature. We present the case of a 62-year-old male with a history of an untreated left adrenal incidentaloma, who was diagnosed four years later with advanced-stage sarcomatoid ACC. Despite surgical and oncologic treatment, the disease progressed rapidly with systemic involvement and limited survival. The histopathological diagnosis is particularly challenging, as this subtype is characterized by the coexistence of epithelial and fusocelular/pleomorphic components with sarcomatoid differentiation, which may hinder its distinction from other primary or metastatic neoplasms. This case underscores the importance of appropriate initial evaluation of adrenal incidentalomas and highlights the highly malignant behavior of this rare variant, emphasizing the need for early diagnosis and timely intervention.

肾上腺皮质癌(ACC)是一种罕见的恶性肿瘤,预后差,对目前的治疗反应有限。肉瘤样亚型是ACC最罕见和最具侵袭性的亚型,文献中报道的病例很少。我们提出的情况下,62岁的男性与一个未经治疗的左肾上腺偶发瘤的历史,谁被诊断为晚期肉瘤样ACC四年后。尽管手术和肿瘤治疗,疾病进展迅速,全身累及和有限的生存。组织病理学诊断尤其具有挑战性,因为该亚型的特征是上皮和梭细胞/多形性成分共存,并伴有肉瘤样分化,这可能阻碍其与其他原发性或转移性肿瘤的区分。该病例强调了对肾上腺偶发瘤进行适当初步评估的重要性,并强调了这种罕见变异的高度恶性行为,强调了早期诊断和及时干预的必要性。
{"title":"[Sarcomatoid variant of adrenocortical carcinoma].","authors":"Silvina Fili, Daniel Moncet, Jorge Zoppi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis and limited response to current therapies. The sarcomatoid subtype represents the rarest and most aggressive form of ACC, with very few cases reported in the literature. We present the case of a 62-year-old male with a history of an untreated left adrenal incidentaloma, who was diagnosed four years later with advanced-stage sarcomatoid ACC. Despite surgical and oncologic treatment, the disease progressed rapidly with systemic involvement and limited survival. The histopathological diagnosis is particularly challenging, as this subtype is characterized by the coexistence of epithelial and fusocelular/pleomorphic components with sarcomatoid differentiation, which may hinder its distinction from other primary or metastatic neoplasms. This case underscores the importance of appropriate initial evaluation of adrenal incidentalomas and highlights the highly malignant behavior of this rare variant, emphasizing the need for early diagnosis and timely intervention.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"229-233"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of Community-Acquired Pneumonia in Adults - Argentine Society of Infectious Diseases]. [成人社区获得性肺炎的管理——阿根廷传染病学会]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Eugenia Di Líbero, Andrea Duarte, Vanesa Kaneshiro, Marcelo Gañete, Sandra Aronson, Maria José López Furst

Community-acquired pneumonia (CAP) is responsible for substantial morbidity and mortality worldwide. Epidemiological surveillance indicates that Streptococcus pneumoniae remains the most frequent etiological agent and the leading cause of mortality. However, with the advent of new diagnostic techniques, viral etiology has gained priority. Chest X-ray is considered mandatory to confirm the diagnosis and establish the spread. Microbiological, antigen, molecular, biomarker, and carriage tests have specific indications and a role to play in reconsidering empirical treatments. Severity scales are useful for defining the site of care, and the most validated prognostic models are PSI and CURB-65. When antibacterial treatment is appropriate, aminopenicillins ± beta-lactamase inhibitors are the preferred treatment, with the addition of a macrolide in severe cases. Pseudomonas and methicillin-resistant Staphylococcus aureus should be considered primarily in patients with a history of prior infection/colonization or severe structural lung disease. Shortened courses have gained support in the literature, and once clinical stability is achieved, it is suggested that treatment be continued for 3-5 days for CAP managed in an outpatient/general ward setting, and 5-7 days for CAP requiring intensive care. The role of corticosteroids in reducing mortality has been documented in severe forms. The benefit of neuraminidase inhibitors for influenza is of low certainty and relatively marginal. Treatments that have had an impact on reducing mortality from severe-critical COVID-19 are corticosteroids, IL-6 receptor blockers, and baricitinib.

社区获得性肺炎(CAP)在世界范围内造成大量发病率和死亡率。流行病学监测表明,肺炎链球菌仍然是最常见的病原体和死亡的主要原因。然而,随着新的诊断技术的出现,病毒病因学得到了优先考虑。胸部x光检查被认为是确认诊断和确定扩散的必要手段。微生物、抗原、分子、生物标志物和载体试验有特定的适应症,在重新考虑经验性治疗中发挥作用。严重程度量表可用于确定治疗部位,最有效的预后模型是PSI和CURB-65。当抗菌治疗合适时,氨基霉素±β -内酰胺酶抑制剂是首选治疗方法,严重者加用大环内酯类药物。假单胞菌和耐甲氧西林金黄色葡萄球菌应主要在既往感染/定植史或严重结构性肺部疾病的患者中考虑。缩短疗程在文献中得到了支持,一旦达到临床稳定,建议在门诊/普通病房管理的CAP继续治疗3-5天,需要重症监护的CAP继续治疗5-7天。皮质类固醇在降低死亡率方面的作用已被严重记录。神经氨酸酶抑制剂对流感的益处是低确定性和相对边缘的。对降低重症COVID-19死亡率有影响的治疗方法是皮质类固醇、IL-6受体阻滞剂和巴比替尼。
{"title":"[Management of Community-Acquired Pneumonia in Adults - Argentine Society of Infectious Diseases].","authors":"Eugenia Di Líbero, Andrea Duarte, Vanesa Kaneshiro, Marcelo Gañete, Sandra Aronson, Maria José López Furst","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Community-acquired pneumonia (CAP) is responsible for substantial morbidity and mortality worldwide. Epidemiological surveillance indicates that Streptococcus pneumoniae remains the most frequent etiological agent and the leading cause of mortality. However, with the advent of new diagnostic techniques, viral etiology has gained priority. Chest X-ray is considered mandatory to confirm the diagnosis and establish the spread. Microbiological, antigen, molecular, biomarker, and carriage tests have specific indications and a role to play in reconsidering empirical treatments. Severity scales are useful for defining the site of care, and the most validated prognostic models are PSI and CURB-65. When antibacterial treatment is appropriate, aminopenicillins ± beta-lactamase inhibitors are the preferred treatment, with the addition of a macrolide in severe cases. Pseudomonas and methicillin-resistant Staphylococcus aureus should be considered primarily in patients with a history of prior infection/colonization or severe structural lung disease. Shortened courses have gained support in the literature, and once clinical stability is achieved, it is suggested that treatment be continued for 3-5 days for CAP managed in an outpatient/general ward setting, and 5-7 days for CAP requiring intensive care. The role of corticosteroids in reducing mortality has been documented in severe forms. The benefit of neuraminidase inhibitors for influenza is of low certainty and relatively marginal. Treatments that have had an impact on reducing mortality from severe-critical COVID-19 are corticosteroids, IL-6 receptor blockers, and baricitinib.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"145-165"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of lenvatinib-induced proteinuria with dapagliflozin. 达格列净治疗lenvatinib诱导的蛋白尿。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
J Matías Calabretta, M Laura Iglesias, Agostina Paggetta, Raul E Giglio, Inés Califano

Proteinuria is an adverse event described in 30% of thyroid cancer patients treated with lenvatinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors. Management of proteinuria is challenging, involving control of arterial hypertension. We describe the case of a patient with advanced radioiodine refractory thyroid cancer treated with lenvatinib who developed late-onset grade 3 proteinuria, despite adequate blood pressure control. He was treated with dapagliflozin 10 mg/day, which promptly improved proteinuria to grade 1. Treatment with lenvatinib was subsequently restarted, with good control of proteinuria. Dapagliflozin is a sodiumglucose co-transporter type 2 (SGLT2) inhibitor that acts in the proximal convoluted tubule, improving renal function in diabetic and non-diabetic patients. SGLT2 inhibitors may have a role in the management of lenvatinib-induced proteinuria, however further study is needed.

lenvatinib是一种靶向血管内皮生长因子受体的酪氨酸激酶抑制剂,在接受lenvatinib治疗的甲状腺癌患者中,30%的患者出现了蛋白尿。蛋白尿的管理是具有挑战性的,包括控制动脉高血压。我们描述了一例晚期放射性碘难治性甲状腺癌患者,接受lenvatinib治疗后,尽管血压得到了适当的控制,但仍发生了迟发性3级蛋白尿。患者接受达格列净10mg /天治疗,蛋白尿迅速改善至1级。随后重新开始lenvatinib治疗,蛋白尿控制良好。达格列净是一种钠葡萄糖共转运蛋白2型(SGLT2)抑制剂,作用于近曲小管,改善糖尿病和非糖尿病患者的肾功能。SGLT2抑制剂可能在lenvatinib诱导的蛋白尿管理中发挥作用,但需要进一步研究。
{"title":"Management of lenvatinib-induced proteinuria with dapagliflozin.","authors":"J Matías Calabretta, M Laura Iglesias, Agostina Paggetta, Raul E Giglio, Inés Califano","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Proteinuria is an adverse event described in 30% of thyroid cancer patients treated with lenvatinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors. Management of proteinuria is challenging, involving control of arterial hypertension. We describe the case of a patient with advanced radioiodine refractory thyroid cancer treated with lenvatinib who developed late-onset grade 3 proteinuria, despite adequate blood pressure control. He was treated with dapagliflozin 10 mg/day, which promptly improved proteinuria to grade 1. Treatment with lenvatinib was subsequently restarted, with good control of proteinuria. Dapagliflozin is a sodiumglucose co-transporter type 2 (SGLT2) inhibitor that acts in the proximal convoluted tubule, improving renal function in diabetic and non-diabetic patients. SGLT2 inhibitors may have a role in the management of lenvatinib-induced proteinuria, however further study is needed.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"224-228"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spanish validation and cross-cultural adaptation of a health recovery expectations scale. 健康恢复期望量表的西班牙语验证和跨文化适应。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Silvana Meek Torres, Lilian Pietracci, María Pía Izaguirre, Diego Caruso

Introduction: This study validates and cross-culturally adapts a Spanish version of the "Provider Expectations for Recovery Scale" (EXPECT-P) and evaluates agreement among patients, families, and physicians regarding recovery expectations after hospitalization.

Materials and methods: Translation of the questionnaire was done by five healthcare professionals. The final version was completed by 42 hospitalized patients aged over 60, their family members, and treating physicians. Patients with dementia, terminal illness, language barriers, or refusal to participate were excluded. Internal consistency was assessed using Cronbach's alpha, and agreement among raters was measured with the intraclass correlation coefficient (ICC).

Results: The median ages of patients, family members, and physicians were 79.5, 56.5, and 35, respectively. Cronbach's alpha values were 0.82, 0.88, and 0.91, respectively. The ICC was 0.71 (95% CI 0.53-0.84, p=0.001). Patients had the highest EXPECT-P scores (median 23.5), followed by family members (median 19.5) and physicians (median 18). Significant differences were observed: 5.5 points between patients and physicians (p<0.001), 4 points between patients and family members (p=0.02), and 1.5 points between physicians and family members (p=0.26).

Discussion: The EXPECT-P Scale showed strong validity and internal consistency. Significant discrepancies in recovery expectations were found between patients, family members, and physicians. These findings highlight the importance of aligning expectations to improve rehabilitation outcomes and reduce potential frustration.

简介:本研究验证并跨文化适应了西班牙语版的“提供者康复期望量表”(EXPECT-P),并评估了患者、家属和医生对住院后康复期望的共识。材料与方法:问卷由5名卫生保健专业人员翻译。最终版本由42名60岁以上的住院患者、他们的家庭成员和治疗医生完成。患有痴呆症、绝症、语言障碍或拒绝参与的患者被排除在外。采用Cronbach’s alpha评估内部一致性,采用类内相关系数(ICC)衡量评分者之间的一致性。结果:患者、家属和医生的中位年龄分别为79.5岁、56.5岁和35岁。Cronbach’s alpha值分别为0.82、0.88和0.91。ICC为0.71 (95% CI 0.53-0.84, p=0.001)。患者的EXPECT-P评分最高(中位数为23.5),其次是家庭成员(中位数为19.5)和医生(中位数为18)。患者和医生之间的差异显著:5.5分(p)讨论:EXPECT-P量表具有较强的效度和内部一致性。患者、家属和医生在康复预期方面存在显著差异。这些发现强调了调整期望对改善康复结果和减少潜在挫折的重要性。
{"title":"Spanish validation and cross-cultural adaptation of a health recovery expectations scale.","authors":"Silvana Meek Torres, Lilian Pietracci, María Pía Izaguirre, Diego Caruso","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>This study validates and cross-culturally adapts a Spanish version of the \"Provider Expectations for Recovery Scale\" (EXPECT-P) and evaluates agreement among patients, families, and physicians regarding recovery expectations after hospitalization.</p><p><strong>Materials and methods: </strong>Translation of the questionnaire was done by five healthcare professionals. The final version was completed by 42 hospitalized patients aged over 60, their family members, and treating physicians. Patients with dementia, terminal illness, language barriers, or refusal to participate were excluded. Internal consistency was assessed using Cronbach's alpha, and agreement among raters was measured with the intraclass correlation coefficient (ICC).</p><p><strong>Results: </strong>The median ages of patients, family members, and physicians were 79.5, 56.5, and 35, respectively. Cronbach's alpha values were 0.82, 0.88, and 0.91, respectively. The ICC was 0.71 (95% CI 0.53-0.84, p=0.001). Patients had the highest EXPECT-P scores (median 23.5), followed by family members (median 19.5) and physicians (median 18). Significant differences were observed: 5.5 points between patients and physicians (p<0.001), 4 points between patients and family members (p=0.02), and 1.5 points between physicians and family members (p=0.26).</p><p><strong>Discussion: </strong>The EXPECT-P Scale showed strong validity and internal consistency. Significant discrepancies in recovery expectations were found between patients, family members, and physicians. These findings highlight the importance of aligning expectations to improve rehabilitation outcomes and reduce potential frustration.</p>","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"84-94"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hildegard of Bingen and her legacy to the history of anatomy and medicine]. [宾根的希尔德加德和她对解剖学和医学史的贡献]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Eduardo Herrera-Aliaga, Manuel E Cortés
{"title":"[Hildegard of Bingen and her legacy to the history of anatomy and medicine].","authors":"Eduardo Herrera-Aliaga, Manuel E Cortés","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"281-282"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[2025 Nobel Prize in Medicine or Physiology]. [2025年诺贝尔医学或生理学奖]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Mirta Giordano
{"title":"[2025 Nobel Prize in Medicine or Physiology].","authors":"Mirta Giordano","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"211-215"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The arrow of time in the brain]. [大脑中的时间之箭]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Basilio A Kotsias
{"title":"[The arrow of time in the brain].","authors":"Basilio A Kotsias","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"283-286"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Ventilator-associated pneumonia in the post-pandemic era]. [大流行后时代的呼吸机相关性肺炎]。
IF 0.6 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-01
Wanda Cornistein, Carina Balasini
{"title":"[Ventilator-associated pneumonia in the post-pandemic era].","authors":"Wanda Cornistein, Carina Balasini","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":18419,"journal":{"name":"Medicina-buenos Aires","volume":"86 1","pages":"277-278"},"PeriodicalIF":0.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicina-buenos Aires
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1